{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T04:48:01Z","timestamp":1776314881140,"version":"3.50.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T00:00:00Z","timestamp":1750464000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T00:00:00Z","timestamp":1750464000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004331","name":"Johnson and Johnson","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004331","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1007\/s11523-025-01163-3","type":"journal-article","created":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T11:11:59Z","timestamp":1750504319000},"page":"737-742","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Dermatologic Adverse Event Mitigation and Management Strategies with Amivantamab\u00a0+\u00a0Lazertinib Therapy for Advanced Non-Small Cell Lung Cancer: A Vodcast"],"prefix":"10.1007","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2479-2271","authenticated-orcid":false,"given":"Danny","family":"Nguyen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edgardo S.","family":"Santos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,6,21]]},"reference":[{"issue":"10","key":"1163_CR1","doi-asserted-by":"publisher","first-page":"815","DOI":"10.2174\/1568026620666200303123102","volume":"20","author":"DA Sabbah","year":"2020","unstructured":"Sabbah DA, Hajjo R, Sweidan K. Review on epidermal growth factor receptor (EGFR) structure, signaling pathways, interactions, and recent updates of EGFR inhibitors. Curr Top Med Chem. 2020;20(10):815\u201334.","journal-title":"Curr Top Med Chem"},{"issue":"7878","key":"1163_CR2","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1038\/s41586-021-03898-1","volume":"597","author":"J Robichaux","year":"2021","unstructured":"Robichaux J, Le X, Vijayan R, Hicks J, Heeke S, Elamin Y, et al. Structure-based classification predicts drug response in EGFR-mutant NSCLC. Nature. 2021;597(7878):732\u20137.","journal-title":"Nature"},{"key":"1163_CR3","doi-asserted-by":"publisher","first-page":"e859","DOI":"10.1016\/j.cllc.2021.04.009","volume":"6","author":"J Leal","year":"2021","unstructured":"Leal J, Alexander M, Itchins M, Wright G, Kao S, Hughes B, et al. EGFR exon 20 insertion mutations: clinicopathological characteristics and treatment outcomes in advanced non-small cell lung cancer. Clin Lung Cancer. 2021;6:e859\u201369.","journal-title":"Clin Lung Cancer"},{"key":"1163_CR4","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41392-019-0038-9","volume":"4","author":"S Vyse","year":"2019","unstructured":"Vyse S, Huang P. Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer. Signal Transduct Target Ther. 2019;4:5.","journal-title":"Signal Transduct Target Ther"},{"key":"1163_CR5","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.semcancer.2019.09.015","volume":"61","author":"P Haarrison","year":"2020","unstructured":"Haarrison P, Vyse S, Huang P. Rare epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer. Semin Cancer Biol. 2020;61:167\u201379.","journal-title":"Semin Cancer Biol"},{"key":"1163_CR6","doi-asserted-by":"publisher","first-page":"6","DOI":"10.21141\/PJP.2018.002","volume":"3","author":"CK Nee-Estuye-Evangelista","year":"2018","unstructured":"Nee-Estuye-Evangelista CK, Andal JJ, Ang D. Frequency of epidermal growth factor receptor mutations among Filipino patients with non-small cell lung carcinoma in private tertiary care setting. PJP. 2018;3:6\u201311.","journal-title":"PJP"},{"issue":"8","key":"1163_CR7","first-page":"1079","volume":"19","author":"ME Lacouture","year":"2011","unstructured":"Lacouture ME, Anadkat MJ, Bensadoun RJ, Bryce J, Chan A, Epstein JB, et al. Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities. Support Care Cancer. 2011;19(8):1079\u201395.","journal-title":"Support Care Cancer"},{"issue":"4","key":"1163_CR8","first-page":"228","volume":"99","author":"CM Rerucha","year":"2019","unstructured":"Rerucha CM, Ewing JT, Oppenlander KE, Cowan WC. Acute hand infections. Am Fam Physician. 2019;99(4):228\u201336.","journal-title":"Am Fam Physician"},{"issue":"2","key":"1163_CR9","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.cllc.2022.11.004","volume":"24","author":"BC Cho","year":"2023","unstructured":"Cho BC, Simi A, Sabari J, Vijayaraghavan S, Moores S, Spira A. Amivantamab, an epidermal growth factor receptor (EGFR) and mesenchymal-epithelial transition factor (MET) bispecific antibody, designed to enable multiple mechanisms of action and broad clinical applications. Clin Lung Cancer. 2023;24(2):89\u201397.","journal-title":"Clin Lung Cancer"},{"key":"1163_CR10","unstructured":"Johnson & Johnson. Rybrevant\u00ae (amivantamab-vmjw) plus Lazcluze\u2122 (lazertinib) approved in the U.S. as a first-line chemotherapy-free treatment for patients with EGFR-mutated advanced lung cancer [press release]. 2024. https:\/\/www.jnj.com\/media-center\/press-releases\/rybrevant-amivantamab-vmjw-plus-lazcluze-lazertinib-approved-in-the-u-s-as-a-first-line-chemotherapy-free-treatment-for-patients-with-egfr-mutated-advanced-lung-cancer. Accessed 18 June 2025."},{"issue":"14","key":"1163_CR11","doi-asserted-by":"publisher","first-page":"3337","DOI":"10.3390\/cancers14143337","volume":"14","author":"A Koulouris","year":"2022","unstructured":"Koulouris A, Tsagkaris C, Corriero AC, Metro G, Mountzios G. Resistance to TKIs in EGFR-mutated non-small cell lung cancer: from mechanisms to new therapeutic strategies. Cancers (Basel). 2022;14(14):3337.","journal-title":"Cancers (Basel)"},{"issue":"16","key":"1163_CR12","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1056\/NEJMoa2403614","volume":"391","author":"BC Cho","year":"2024","unstructured":"Cho BC, Lu S, Felip E, Spira AI, Girard N, Lee JS, et al. Amivantamab plus lazertinib in previously untreated EGFR-mutated advanced NSCLC. N Engl J Med. 2024;391(16):1486\u201398.","journal-title":"N Engl J Med"},{"key":"1163_CR13","unstructured":"Food & Drug Administration (FDA). FDA approves lazertinib with amivantamab-vmjw for non-small lung cancer [press release]. 2024. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-lazertinib-amivantamab-vmjw-non-small-lung-cancer. Accessed 18 June 2025."},{"key":"1163_CR14","unstructured":"Johnson & Johnson. European Commission approves Lazcluze\u00ae (lazertinib) in combination with Rybrevant\u00ae (amivantamab) for the first-line treatment of patients with EGFR-mutated advanced non-small cell lung cancer [press release]. 2025. https:\/\/www.jnj.com\/media-center\/press-releases\/european-commission-approves-lazcluze-lazertinib-in-combination-with-rybrevant-amivantamab-for-the-first-line-treatment-of-patients-with-egfr-mutated-advanced-non-small-cell-lung-cancer. Accessed 18 June 2025."},{"key":"1163_CR15","unstructured":"Rybrevant (amivantamab-vmjw) injection. Prescribing information. Horsham (PA): Janssen Biotech, Inc.; 2021."},{"key":"1163_CR16","unstructured":"Lazcluze\u2122 (lazertinib) injection. Prescribing information. Horsham (PA): Janssen Biotech, Inc.; 2024."},{"issue":"2","key":"1163_CR17","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.annonc.2020.11.005","volume":"32","author":"ME Lacouture","year":"2021","unstructured":"Lacouture ME, Sibaud V, Gerber PA, van den Hurk C, Fern\u00e1ndez-Pe\u00f1as P, Santini D, et al. Prevention and management of dermatological toxicities related to anticancer agents: ESMO Clinical Practice Guidelines. Ann Oncol. 2021;32(2):157\u201370.","journal-title":"Ann Oncol"},{"issue":"4","key":"1163_CR18","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.3390\/curroncol29040205","volume":"29","author":"A Zereshkian","year":"2022","unstructured":"Zereshkian A, Thawer A, Hwang DM, Cheng S. EGFR targeting TKI-related skin toxicities in a patient with darker skin: a case report. Curr Oncol. 2022;29(4):2509\u201315.","journal-title":"Curr Oncol"},{"issue":"4","key":"1163_CR19","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1097\/CCO.0b013e3283474063","volume":"23","author":"PA Wu","year":"2011","unstructured":"Wu PA, Balagula Y, Lacouture ME, Anadkat MJ. Prophylaxis and treatment of dermatologic adverse events from epidermal growth factor receptor inhibitors. Curr Opin Oncol. 2011;23(4):343\u201351.","journal-title":"Curr Opin Oncol"},{"issue":"8","key":"1163_CR20","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1634\/theoncologist.2017-0582","volume":"23","author":"CY Chu","year":"2018","unstructured":"Chu CY, Choi J, Eaby-Sandy B, Langer CJ, Lacouture ME. Osimertinib: a novel dermatologic adverse event profile in patients with lung cancer. Oncologist. 2018;23(8):891\u20139.","journal-title":"Oncologist"},{"issue":"2","key":"1163_CR21","first-page":"513","volume":"24","author":"JMK Clabbers","year":"2016","unstructured":"Clabbers JMK, Boers-Doets CB, Gelderblom H, Stijnen T, Lacouture ME, van der Hoeven KJM, et al. Xerosis and pruritus as major EGFRI-associated adverse events. Support Care Cancer. 2016;24(2):513\u201321.","journal-title":"Support Care Cancer"},{"issue":"22","key":"1163_CR22","doi-asserted-by":"publisher","first-page":"3969","DOI":"10.1002\/cncr.34474","volume":"128","author":"T Zhou","year":"2022","unstructured":"Zhou T, Zhang Y, Ma Y, Ma W, Wu X, Huang L, et al. Comparison of aprepitant versus desloratadine for EGFR-TKI-induced pruritus: a randomized phase 2 clinical trial. Cancer. 2022;128(22):3969\u201376.","journal-title":"Cancer"},{"issue":"30","key":"1163_CR23","doi-asserted-by":"publisher","first-page":"3593","DOI":"10.1200\/JCO.24.01001","volume":"42","author":"N Leighl","year":"2024","unstructured":"Leighl N, Akamatsu H, Lim SM, Cheng Y, Minchom AR, Marmarelis ME, et al. Subcutaneous versus intravenous amivantamab, both in combination with lazertinib, in refractory epidermal growth factor receptor-mutated non-small cell lung cancer: primary results from the phase III PALOMA-3 study. J Clin Oncol. 2024;42(30):3593\u2013605.","journal-title":"J Clin Oncol"},{"key":"1163_CR24","doi-asserted-by":"crossref","unstructured":"Cho BC, Girard N, Sauder MB, et al. Enhanced vs standard dermatologic management with amivantamab-lazertinib in advanced NSCLC: phase 2 COCOON study. Presented at: 2024 World Conference on Lung Cancer; 7-10 September 2024; San Diego (CA). Abstract P3.12D.04.","DOI":"10.1016\/j.jtho.2024.09.626"},{"key":"1163_CR25","doi-asserted-by":"crossref","unstructured":"Girard N, Li W, Spira A, Feldman J, Mak M, Sauder MB, et al. Preventing moderate to severe dermatologic adverse events in first-line EGFR-mutant advanced NSCLC treated with amivantamab plus lazertinib: early success of the COCOON trial. Presented at: 2025 European Lung Cancer Congress; 26\u201329 March 2025; Paris. Abstract 10MO.","DOI":"10.1016\/S1556-0864(25)00205-9"}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-025-01163-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11523-025-01163-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-025-01163-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T13:04:23Z","timestamp":1758719063000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11523-025-01163-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,21]]},"references-count":25,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["1163"],"URL":"https:\/\/doi.org\/10.1007\/s11523-025-01163-3","relation":{},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"value":"1776-2596","type":"print"},{"value":"1776-260X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,21]]},"assertion":[{"value":"14 June 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was funded by Johnson & Johnson.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Danny Nguyen reports: honoraria\/advisory role: Novartis and Takeda; stock or other ownership interests: Intuitive Surgical and Teladoc. Edgardo S. Santos reports: advisory board or panel\/consultant: AZ, AbbVie, Regeneron, Novartis, Johnson & Johnson, BI, Novocure, and EMD Serono; speaker bureau: Amgen, AZ, BMS, BI, Lilly, Pharmacosmos, Jazz Pharmaceuticals, Johnson & Johnson, Merck, Pfizer, Regeneron, Coherus, Takeda, and Novocure.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest\/Competing Interests"}},{"value":"The MARIPOSA and COCOON studies were conducted in accordance with the principles of the Declaration of Helsinki and the Good Clinical Guidelines of the International Council for Harmonisation. The protocol and amendments were approved by the institutional review board at each study site.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"All patients provided written informed consent for these studies.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The data sharing policy of Johnson & Johnson is available at . As noted on this site, requests for access to the study data can be submitted through the Yale Open Data Access (YODA) Project site at .","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"DN: conceptualization; data curation; writing (original draft); and writing (review and editing). ESS: conceptualization; data curation; writing (original draft); and writing (review and editing).","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}